EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update

Pavel V Chernyshov iD, Gregor Jemec iD, Andrew Finlay iD, John R Ingram iD, Carmen Salavastru iD, Lucia Tomas-Aragones iD, Servando Marron iD, Dimitra Koumaki iD, Jacek Szepietowski iD, Stamatios Gregoriou iD, Uwe Gieler iD, Matthias Augustin iD und 17 weitere

International Journal of Dermatology · 2026

DOI: 10.1111/ijd.70443 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Pavel V Chernyshov und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Bogomolets National Medical University, Kyiv, Ukraine. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Quality of Life. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS) has a profound negative impact on patients' Quality of Life (QoL). The European Academy of Dermatology and Venereology (EADV) Task Force (TF) on QoL and Patient Oriented Outcomes and TF on Acne, Rosacea and Hidradenitis Suppurativa (ARHS), together with external experts, decided to provide an updated position statement on QoL measurement in HS. In our previous position statement on HS, we stated that a Dermatology Life Quality Index (DLQI) score of 0–1, corresponding to no effect on patient's life according to the DLQI banding descriptions, may be considered as a difficult to reach but important treatment goal: achievement of this goal has since been used as an efficacy criterion in several clinical trials. For many HS treatment methods, there is still a lack of well‐organized randomized clinical trials with sufficient participant numbers in which QoL instruments have been used as outcome measures. The DLQI is the most widely used QoL instrument in HS. Clinical recommendations and treatment efficacy are based on its score grading system and minimal clinically important difference (MCID). The HS‐specific QoL instruments HSIA, HSQoL‐24, HiSQOL, and QoL‐HS have a satisfactory number of items for routine clinical use and short recall periods. HiSQOL and HSQoL‐24 have score grading systems and the MCID for HiSQOL has been established. The TF on QoL and Patient Oriented Outcomes and TF on ARHS recommend that QoL be assessed in HS: dermatology‐specific and HS‐specific instruments may be used alongside each other.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaQuality of LifeHumansMinimal Clinically Important DifferenceSeverity of Illness IndexDermatology

Stichwörter der Autor:innen

hidradenitis suppurativameasurementquality of lifetreatment

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Bogomolets National Medical University, Kyiv, Ukraine.
  • Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
  • Department of Paediatric Dermatology, Colentina Clinical Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Department of Psychology, University of Zaragoza, Zaragoza, Spain.

ORCID-Profile: Pavel V Chernyshov, Gregor Jemec, Andrew Finlay, John R Ingram, Carmen Salavastru, Lucia Tomas-Aragones, Servando Marron, Dimitra Koumaki, Jacek Szepietowski, Stamatios Gregoriou, Uwe Gieler, Matthias Augustin, Anthony Bewley, Alina Suru, Francesca Sampogna, Ake Svensson, Nives Pustisek, Razvigor Darlenski, Damiano Abeni, Sam Salek, Liana Manolache, Thrasyvoulos Tzellos, Iurii Kuchyn, Serhiy Zemskov, Ruslan Tsymbaliuk, Oksana Zemskova, Alejandro Molina Leyva, Christos C Zouboulis

Zitieren

APA

Chernyshov, P. V., Jemec, G., Finlay, A., Ingram, J. R., Salavastru, C., Tomas-Aragones, L., Marron, S., Koumaki, D., Szepietowski, J., Gregoriou, S., Gieler, U., Augustin, M., Bewley, A., Suru, A., Sampogna, F., Svensson, A., Pustisek, N., Darlenski, R., Abeni, D., …, & Zouboulis, C. C. (2026). Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update. International Journal of Dermatology. https://doi.org/10.1111/ijd.70443

Vancouver

Chernyshov PV, Jemec G, Finlay A, Ingram JR, Salavastru C, Tomas-Aragones L, et al. Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update. International Journal of Dermatology. 2026. doi:10.1111/ijd.70443

BibTeX
@article{Chernyshov2026,
  author = {Chernyshov, Pavel V and Jemec, Gregor and Finlay, Andrew and Ingram, John R and Salavastru, Carmen and Tomas-Aragones, Lucia and Marron, Servando and Koumaki, Dimitra and Szepietowski, Jacek and Gregoriou, Stamatios and Gieler, Uwe and Augustin, Matthias and Bewley, Anthony and Suru, Alina and Sampogna, Francesca and Svensson, Ake and Pustisek, Nives and Darlenski, Razvigor and Abeni, Damiano and Salek, Sam and Manolache, Liana and Tzellos, Thrasyvoulos and Kuchyn, Iurii and Zemskov, Serhiy and Tsymbaliuk, Ruslan and Zemskova, Oksana and Molina Leyva, Alejandro and Boffa, Michael J and Zouboulis, Christos C},
  title = {Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70443}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche